Efficacy of Brahmi vati and Aswagandharista (Ayurvedamedication) in major depressive disorder: A randomized controlled trial Authors: Amit Sarhyal, Sameeran Chate, Basavaraj R. Tubaki, Rajat Thakur Published: 2024 ABSTRACT BackgroundRole of Ayurveda medications in the management of Major depressive disorder (MDD) is explored.ObjectiveTo evaluate the effect of Brahmi vati and Aswagandarista in the management of MDD.MethodsStudy was a Randomized, Controlled, parallel group comparative clinical trial. Fifty patients meeting the MDD (DSM V) diagnostic criteria from teaching hospital were recruited in the study. They were divided in two 2 groups. Control group were administered with Escitalopram 10 mg twice a day. Ayurveda group were intervened with tablet Brahmi vati 500 mg thrice a day and Liquid Aswagandarista 10 ml thrice a day. Interventions were for 60 days. Assessments were done on every 15th day. Assessments criteria included Hamilton Depression Rating scale (HDRS), Hamilton Anxiety Rating scale (HARS), UKU Side effect scale (UKU), Brief Psychotic Rating Scale (BPRS), WHO quality of life -BREF (WHOQOL-BREF), Pittsburgh Sleep Quality Index (PSQI) and Clinical Global Impression scales (CGI) were assessed at all the time points. Blood parameters like Haemoglobin, Serum creatinine and Liver function tests were evaluated at pre and post study.ResultsBetween group comparison showed significant improvements in WHOQOL-Bref (p < 0.001), UKU (p = 0.04) favouring Ayurveda group and PSQI (p = 0.02) improvements in control group. Improvements in other parameters were comparable. Within group assessment showed significant (p < 0.001) improvement in HDRS, HARS, BPRS, CGI-S, CGI-GI in both the groups. Liver function tests and serum creatines were within normative limits.ConclusionAyurveda medications produced significant improvements comparable to escitalopram with additional advantages in quality of life and side effects profile. Introduction Depression is a highly prevalent chronic medical illness that has significant mortality and morbidity. Predominant manifestations include sadness, loss of interest, feeling of guilt, low self worth, poor concentration and disturbed sleep. Major depressive disorder (MDD) is a type of depressive disorder associated with depressed mood, suicidal tendencies, fatigue or loss of energy, psychomotor agitation, insomnia, persisting most of the day, nearly every day for a period of two weeks [1]. It is a chronic illness with recurrent episodes associated with gross impairment of quality of life, interpersonal relationships and professional life. MDD occurs in 10–15% of the population and is projected to become the second leading cause of disease and disability worldwide by 2030 [2]. Nearly 350 million people are affected worldwide [3] and the overall burden ranks among the highest of all the diseases [4]. Twelve month prevalence of MDD is 6.6% and lifetime is 16.2%, twice common in women than men and has considerable effect [5]. Indian population study [6] showed overall prevalence of depression as 15.9%. Depression is associated with increased risk for suicide, substance abuse and other medical conditions like heart disease, diabetes mellitus and stroke [7]. Pharmacotherapy in depression includes tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI), selective monoamine oxidase inhibitors and specific serotonin nor-adrenaline reuptake inhibitors (SNRI) [8]. Escitalopram has shown better safety and efficacy profile among all the SSRI and SNRI drugs in depression [9]. Recurrent episodes are observed in 60% patients of MDD and each successive episode has 10–20% risk of failure in remittance with current therapeutics [10]. A Meta-analysis [11] showed that all antidepressants were more efficacious than placebo and had modest effect size. But have few limitations. Complete effect of antidepressants begins after weeks of treatment and this may lead to poor response, dropouts in the treatment. Few antidepressants may produce adverse events on long term use and which may not be picked up by acute phase treatment studies or shorter duration intervention studies. In unpublished data, antidepressants were associated with less favourable effect sizes [12]. Few antidepressants produce weight gain and that can worsen or induce primary sleep disorders like restless legs syndrome, sleep apnea [13]. Sixty-eight percent of patients do not respond to a first-line course of antidepressant treatment, and fifteen to thirty percent of depressive episodes do not improve with appropriate trials of two antidepressants [14]. More number of patients are increasingly using Complementary and Alternative Medicine (CAM). CAM therapies are used by 40% of adults with depression [15]. However the CAM lacks data on therapeutic efficacy and safety. There is paucity of Ayurveda interventional studies on MDD. For CAM including ayurveda to be accepted globally, they need to produce evidences for efficacy and safety [16]. Ayurveda describes depressive disorders under the disease Vishada and Kaphaja Unmada. Pathophysiology includes Tama dosha along with kapha and vata dosha derangements. Ayurveda physicians use various drugs like Brahmi vati [17], Aswagandharista [18] in management of MDD in their clinical settings. Brahmi vati is a herbomineral preparation with ingredients like Brahmi (Bacoppa monnieri (L.) Pennell), Shankhapushpi (Convolvulus pluricaulis Choisy), Vacha (Acorus calamus), Swarnamakshika (Chalcopyrite), Rasa sindoora (Red sulphide of mercury) and Jatamamsi (Nardostachys jatamamsi. DC) etc. It has shown beneficial effect in patients of Generalized Anxiety disorder [19] and Essential Hypertension [20]. It has ingredients that have medhya (nootropic), rasayana (rejuvenative), nidrajanana (sleep promoting). Aswagandharista has ingredients like Ashwagandha (Withania somnifera Dunal), Shweta Musali (Chlorophytum borivilianum), Manjistha (Rubia cordifolia L), Musta (Cyperus rotundus), Vidari (Puraria tuberosa DC.) etc. It is indicated in Unmada (Psychiatric disorders along with psychotic disorders), apasmara (epilepsy), murcha (syncope). Aswagandharista has shown to have antiepileptic activity in animal model [21]. Human study with Aswagandha has shown to reduce depression in patients of schizophrenia or schizoaffective disorder and healthy, stressed participants [22]. Hence current study is planned to evaluate the efficacy of Ayurveda drugs, Brahmi vati along with Aswagandharista in the management of MDD. Materials and methods The patient attending outpatient department of the institute were recruited for the study. Study reporting is as per the CONSORT statement guidelines [23]. Patients Total 50 patients diagnosed as Major Depressive Disorder as per DSM V criteria [24] were recruited from patients visiting outpatient department of KAHER's shri BMK Ayurveda hospital Belagavi, Karnataka India. The patients of either sex between 20 and 60 years of age were enrolled in the study. The patients with Axis II disorders, other Axis I disorders, evidence of active suicidal ideations, depression with psychotic symptoms were excluded. Patients with other comorbid medical conditions like hypertension, use of psychotropic's therapy/drugs within the past period of 4 weeks, pregnant and lactating females patients were excluded from the study. Screening methods Study information materials like brochures and pamphlets were circulated to patient visiting hospital, camps and in reception area of the hospital. AS and BRT communicated to all the patients and patient attenders personally. Patient (n = 68) meeting the MDD criteria for DSM V were screened to enrol 50 patients in the study. All patients were evaluated carefully and systematic data recording was done. Laboratory and Ayurveda variables like Prakruti were assessed. Laboratory assessments were carried out at Clinical Laboratory, KAHER's BMK Ayurveda Mahavidyalaya, Belagavi in all the patients at baseline and on 60th day of intervention. Research design The study was a Randomized, Controlled, parallel group comparative clinical study. The team involved in randomization, distribution and administration of study materials were independent from investigators. Random numbers were generated from online software named as “Random Number Generator”. Block size was 2. The patients were allocated in control and intervention groups in 1:1 ratio. Principal investigator generated the sequence and packed in a sealed envelope. Opaque sealed envelope was used for allocation concealment. Based on a previous publication [25], estimated effect size of d = 0.79, alpha error = 0.05 (two tailed as direction was not hypothesised) power = 0.08, we estimated that we require 25 participants in each group. Intervention All the patients (n = 50) were randomly divided into two groups: Control group and Ayurveda group. Control group (n = 25) received Escitalopram tablets 10 mg twice a day for 60 days. Ayurveda group (n = 25) received Ashwagandharishta 10 ml thrice a day and Brahmi vati 500 mg thrice a day for 60 days. All interventions were administered with water after food intake. Escitalopram is a selective serotonin reuptake inhibitors (SSRI), which is commonly used for treatment of the major depressive disorder (MDD) and Anxiety disorders [26]. Brahmi vati and Ashwagandharista are the formulations from the classical text books of Ayurveda. Preparation of Bramhi vati and Ashwagandharishta were carried out at GMP certified KLE Ayurveda Pharmacy, Khasbhag, Belagavi. The ingredients of Brahmi vati and Ashwagandharishta were procured from reliable sources. Authentication of all raw material were done at Central Research Facility (Ministry of AYUSH Govt of India approved) ASU (Ayurveda, Siddha and Unani) drug testing laboratory. Qualitative analysis of each raw material and finished product were as per API (Ayurvedic Pharmacopeia of India) guidelines. Raw drugs (ash, extractive values and loss on drying), finished product assessments were done. For powder of Brahmi vati, ash values and loss on drying were assessed and capsule filling was done. For Aswagandharista, macroscopic assessments included form, colour, taste and in physicochemical standards specific gravity, pH value, total solids, reducing sugars, nonreducing sugars, alcohol content were assessed. Escitalopram was procured from Richfield pharmaceuticals Karnataka, India as per the standard procedures. Duration of intervention was 60 days with follow-up on every 15th day. Patients were educated with the study details and informed consent was obtained. Study was conducted in accordance with the declaration of Helsinki. The study was approved by the Institutional Ethics Committee, protocol id BMK/16/PG/KC04, KAHER's BMK Ayurveda Mahavidyalaya Belagavi, Date of Approval July 21, 2017 and CTRI Registration Number CTRI2019/01/017227. Data collection was from August 2017 to May 2019. Patients asked to follow the instructions and details provided. Any adverse events were asked to report at the earliest. Any clinical manifestations causing significant distress were assessed for the possible adverse event. Criteria for assessment Primary outcome The primary outcome was evaluated by Hamilton Depression Rating scale (HDRS) [27]. Secondary outcome The secondary outcomes like Hamilton Anxiety Rating scale (HARS) [28], UKU Side effect scale [29], Brief Psychotic Rating Scale (BPRS) [30], WHO quality of life -BREF (WHOQOL-BREF) [31], Pittsburgh Sleep Quality Index (PSQI) [32] and Clinical Global Impression {Severity (CGI-S), Global Improvement (CGI-GI), Efficacy Index(CGI-EI)} [33] were assessed at all the time points. Blood parameters like Haemoglobin, serum creatinine and liver function tests like bilirubin total, bilirubin direct, bilirubin indirect, Aspartate Amino transferase, Alanine Amino transferase, Alkaline phosphatase, total protein, albumin were assessed at pre and post interventions. Statistical methods All the statistical analysis were carried out in SPSS version 25.0. Homogeneity of the data across the groups was evaluated by the χ2 test. Comparison between groups across different time point was assessed by repeated measure ANOVA test and within group comparison was carried out by Bonferroni post-hoc test. In objective parameters independent paired T test was applied. Values are reported as mean ± standard deviation. Effect size was calculated by Partial Eta Square method. Effect of treatment was evaluated through outcome from base line to 30th day and 60th day. Effect size interpretation was 0–0.2 minimal, 0.2–0.5 was small, 0.5 to 0.8 was medium and above 0.8 was large effect [34] size. All tests were considered statistically significant at p < 0.05. Results Total patients enrolled in the study were 50. Twenty two patients completed the study in control group and 3 patients dropped out. Reasons were intercurrent illness of fever in 2 patients and due to migration was in another patient. Twenty three patients completed study in Ayurveda group and 2 patients dropped out. Drop out reason was migration in both the patients (Fig. 1).Fig. 1Subject flow chart through the study.Fig. 1 Subject flow chart through the study. Patient profile Mean age of the patients was 43.94 years. Majority of patients were female (52%), middle socioeconomic status (54%), mixed diet pattern (66%), graduate (42%), Vata pitta prakruti (66%), married (70%), had no family history of depression (94%) and disturbed sleep (100%). Mean duration of illness was 2.26 years. Mean BMI was 23.97 and mean weight was 58.63 kgs. The mean age (p = 0.45), gender (p = 0.57), socio economic status (p = 0.38), education (p = 0.43), diet pattern (p = 0.76) were comparable between groups (Table 1). Clinical variables like prakruti (p = 0.59), weight (p = 0.46), body mass index (p = 0.52), duration of illness (p = 0.09), and history of sleep disturbance of the patients were comparable in both the groups (Table 1). Clinical assessments at base line like HDRS, HARS, BPRS, PSQI, WHOQOL-Bref, CGI severity (Table 2), Haemoglobin, Serum creatinine, Liver function tests like Bilirubin total, Bilirubin direct, bilirubin indirect, Aspartate Amino transferase, Alanine Amino transferase, Alkaline phosphatase, total protein, albumin (Table 4) were comparable between the groups.Table 1Patient profile: Expressed in Mean, standard deviations (S.D.) and percentage.Table 1S.NoClinical ProfileControl GroupAyurveda GroupTotalp valueNo%No%1Age (years)44.32 ± 11.2343.56 ± 11.5143.94 ± 11.260.452Male1144%1352%24 (48%)0.57Female1456%1248%26 (52%)3Socio Economic Status - Poor28%416%6 (12%)0.38Socio Economic Status - Middle class2392%2184%54 (88%)4Food - Vegetarian832%936%17 (34%)0.76Mixed1768%1664%33 (66%)5Educational Status- Illiterate416%14%5 10(%)0.43Primary416%728%11 (22%)Secondary624%728%13 (26%)Graduate1144%1040%21 (42%)6Prakruti (Body constitution)-0.59Pitta Kapha14%01(2%)Vata Pitta1664%1768%33(66%)Vata Kapha832%832%16(32%)7Marital StatusUnmarried216%832%10 (20%)0.19Married2080%1560%35(70%)Divorse14%14%2(4%)Widow28%14%3(6%)8Family HistoryYes14%28%3(6%)0.55No2496%2392%47(94%)9Sleep disturbance - Yes25100%25100%50(100%)10Duration of illness (years)1.75 ± 1.392.76 ± 2.622.26 ± 2.140.0911Weight (kgs)59.90 ± 11.5557.36 ± 12.6658.63 ± 12.060.4612BMI24.36 ± 4.2423.57 ± 4.4423.97 ± 4.310.5213Dropouts312%28%5 (10%)14Study completed2288%2392%45 (90%)Total252550Table 2Baseline characteristics of clinical assessment scales in two groups - HDRS Hamilton Anxiety Rating scale.Table 2S.noParameterControl Group (Mean + S.D.)Ayurveda Group (Mean + S.D.)p1.HDRS24.56 ± 6.3423.76 ± 5.970.6482.HARS24.72 ± 5.9624.56 ± 6.670.9293.BPRS38.28 ± 7.0838.08 ± 9.530.9334.PSQI11.12 ± 3.1110.64 ± 2.880.5745.WHOQOL-Bref71.48 ± 14.7565.96 ± 15.010.1966.CGI-S4.48 ± 1.004.52 ± 0.870.881Table 3Effect of interventions on clinical assessment scales.Table 3S.NoParametersGpBase line (Mean + S.D.)15th day (Mean + S.D.)30th day (Mean + S.D.)45th day (Mean + S.D.)60th day (Mean + S.D.)Difference of pre & postp valueEffectSize (0–60 days)C-ControlA-Ayurveda1HDRSC24.56 ± 6.3420.17 ± 6.8815.23 ± 8.9912.45 ± 9.6110.32 ± 9.8114.31 ± 10.470.790.08A23.76 ± 5.9720.67 ± 5.1415.70 ± 8.0411.09 ± 6.549.57 ± 6.7013.56 ± 7.082HARSC24.72 ± 5.9621.87 ± 6.2917.77 ± 8.5313.36 ± 10.3810.86 ± 10.5813.54 ± 10.290.240.36A24.56 ± 6.6722.50 ± 7.4718.78 ± 8.8615.35 ± 7.9213.83 ± 9.3910.30 ± 7.703BPRSC38.28 ± 7.0835.61 ± 7.5530.36 ± 7.4828.00 ± 8.6125.23 ± 8.4413.72 ± 9.460.290.33A38.08 ± 9.5336.25 ± 10.0932.35 ± 10.9329.78 ± 9.9627.30 ± 10.5010.95 ± 7.744PSQIC11.12 ± 3.119.13 ± 4.088.23 ± 3.537.68 ± 3.577.50 ± 3.643.72 ± 3.290.020.72A10.64 ± 2.8810.00 ± 3.289.39 ± 3.408.87 ± 3.548.70 ± 3.221.73 ± 2.115WHOQOL-BrefC71.48 ± 14.7575.54 ± 15.8977.04 ± 17.5777.18 ± 16.3776.36 ± 15.733.63 ± 7.58<0.0012.82A65.96 ± 15.0167.83 ± 15.3675.00 ± 15.5379.95 ± 13.4086.52 ± 14.2421.26 ± 4.666CGI-SC4.48 ± 1.004.30 ± 1.253.59 ± 1.362.95 ± 1.612.77 ± 1.791.77 ± 1.230.310.23A4.52 ± 0.874.37 ± 0.823.86 ± 0.963.52 ± 0.793.13 ± 1.251.43 ± 0.947CGI-GIC–3.56 ± 0.943.13 ± 0.992.63 ± 1.172.31 ± 1.171.22 ± 0.750.300.31A–4.29 ± 0.803.56 ± 0.943.30 ± 0.822.73 ± 0.811.47 ± 0.848CGI-EIC–9.95 ± 3.507.00 ± 3.325.86 ± 3.624.68 ± 4.095.13 ± 4.120.300.32A–10.95 ± 2.839.13 ± 2.947.96 ± 3.187.00 ± 3.913.82 ± 4.169UKUC–0.31 ± 0.710.0390.62A–0Table 4Effect of interventions on haematological and biochemical variables.Table 4Sl.NoParameterIntervention PeriodControl Group (Mean + S.D.)Ayurveda Group (Mean + S.D.)pEffect Size (0–60 days)1Haemoglobin (mg/dL)0 day12.34 ± 1.7812.28 ± 1.740.750.0160 day12.22 ± 1.3812.14 ± 1.750.8752Serum Creatinine (mg/dl)0 day0.922 ± 0.090.96 ± 0.100.0350.1760 day0.95 ± 0.090.96 ± 0.130.8553Total Bilirubin (mg/dL)0 day0.59 ± 0.100.60 ± 0.091.000.0860 day0.62 ± 0.210.60 ± 0.090.644Direct Biluribin (mg/dL)0 day0.12 ± 0.040.19 ± 0.250.130.3560 day0.11 ± 0.030.11 ± 0.030.735AST (IU/mL)0 day20.72 ± 3.6020.60 ± 4.340.940.0960 day20.22 ± 2.1821.56 ± 4.410.206ALT (IU/mL)0 day18.59 ± 2.2619.69 ± 4.330.190.0860 day19.31 ± 4.5320.08 ± 2.890.507Total Protein (mg/dL)0 day6.70 ± 0.396.69 ± 0.280.700.0760 day6.66 ± 0.286.71 ± 0.270.558Albumin (mg/dL)0 day3.50 ± 0.393.53 ± 0.270.960.0560 day3.58 ± 0.283.59 ± 0.260.939Albumin Globulin ratio0 day1.05 ± 0.141.01 ± 0.040.270.0760 day1.07 ± 0.101.05 ± 0.090.4910Alkaline Phosphatase (IU/mL)0 day83.27 ± 26.9875.17 ± 9.620.050.2560 day118.68 ± 31.79102.43 ± 28.470.078p<0.001<0.001 Table 1Patient profile: Expressed in Mean, standard deviations (S.D.) and percentage.Table 1S.NoClinical ProfileControl GroupAyurveda GroupTotalp valueNo%No%1Age (years)44.32 ± 11.2343.56 ± 11.5143.94 ± 11.260.452Male1144%1352%24 (48%)0.57Female1456%1248%26 (52%)3Socio Economic Status - Poor28%416%6 (12%)0.38Socio Economic Status - Middle class2392%2184%54 (88%)4Food - Vegetarian832%936%17 (34%)0.76Mixed1768%1664%33 (66%)5Educational Status- Illiterate416%14%5 10(%)0.43Primary416%728%11 (22%)Secondary624%728%13 (26%)Graduate1144%1040%21 (42%)6Prakruti (Body constitution)-0.59Pitta Kapha14%01(2%)Vata Pitta1664%1768%33(66%)Vata Kapha832%832%16(32%)7Marital StatusUnmarried216%832%10 (20%)0.19Married2080%1560%35(70%)Divorse14%14%2(4%)Widow28%14%3(6%)8Family HistoryYes14%28%3(6%)0.55No2496%2392%47(94%)9Sleep disturbance - Yes25100%25100%50(100%)10Duration of illness (years)1.75 ± 1.392.76 ± 2.622.26 ± 2.140.0911Weight (kgs)59.90 ± 11.5557.36 ± 12.6658.63 ± 12.060.4612BMI24.36 ± 4.2423.57 ± 4.4423.97 ± 4.310.5213Dropouts312%28%5 (10%)14Study completed2288%2392%45 (90%)Total252550 Patient profile: Expressed in Mean, standard deviations (S.D.) and percentage. Table 2Baseline characteristics of clinical assessment scales in two groups - HDRS Hamilton Anxiety Rating scale.Table 2S.noParameterControl Group (Mean + S.D.)Ayurveda Group (Mean + S.D.)p1.HDRS24.56 ± 6.3423.76 ± 5.970.6482.HARS24.72 ± 5.9624.56 ± 6.670.9293.BPRS38.28 ± 7.0838.08 ± 9.530.9334.PSQI11.12 ± 3.1110.64 ± 2.880.5745.WHOQOL-Bref71.48 ± 14.7565.96 ± 15.010.1966.CGI-S4.48 ± 1.004.52 ± 0.870.881 Baseline characteristics of clinical assessment scales in two groups - HDRS Hamilton Anxiety Rating scale. Table 3Effect of interventions on clinical assessment scales.Table 3S.NoParametersGpBase line (Mean + S.D.)15th day (Mean + S.D.)30th day (Mean + S.D.)45th day (Mean + S.D.)60th day (Mean + S.D.)Difference of pre & postp valueEffectSize (0–60 days)C-ControlA-Ayurveda1HDRSC24.56 ± 6.3420.17 ± 6.8815.23 ± 8.9912.45 ± 9.6110.32 ± 9.8114.31 ± 10.470.790.08A23.76 ± 5.9720.67 ± 5.1415.70 ± 8.0411.09 ± 6.549.57 ± 6.7013.56 ± 7.082HARSC24.72 ± 5.9621.87 ± 6.2917.77 ± 8.5313.36 ± 10.3810.86 ± 10.5813.54 ± 10.290.240.36A24.56 ± 6.6722.50 ± 7.4718.78 ± 8.8615.35 ± 7.9213.83 ± 9.3910.30 ± 7.703BPRSC38.28 ± 7.0835.61 ± 7.5530.36 ± 7.4828.00 ± 8.6125.23 ± 8.4413.72 ± 9.460.290.33A38.08 ± 9.5336.25 ± 10.0932.35 ± 10.9329.78 ± 9.9627.30 ± 10.5010.95 ± 7.744PSQIC11.12 ± 3.119.13 ± 4.088.23 ± 3.537.68 ± 3.577.50 ± 3.643.72 ± 3.290.020.72A10.64 ± 2.8810.00 ± 3.289.39 ± 3.408.87 ± 3.548.70 ± 3.221.73 ± 2.115WHOQOL-BrefC71.48 ± 14.7575.54 ± 15.8977.04 ± 17.5777.18 ± 16.3776.36 ± 15.733.63 ± 7.58<0.0012.82A65.96 ± 15.0167.83 ± 15.3675.00 ± 15.5379.95 ± 13.4086.52 ± 14.2421.26 ± 4.666CGI-SC4.48 ± 1.004.30 ± 1.253.59 ± 1.362.95 ± 1.612.77 ± 1.791.77 ± 1.230.310.23A4.52 ± 0.874.37 ± 0.823.86 ± 0.963.52 ± 0.793.13 ± 1.251.43 ± 0.947CGI-GIC–3.56 ± 0.943.13 ± 0.992.63 ± 1.172.31 ± 1.171.22 ± 0.750.300.31A–4.29 ± 0.803.56 ± 0.943.30 ± 0.822.73 ± 0.811.47 ± 0.848CGI-EIC–9.95 ± 3.507.00 ± 3.325.86 ± 3.624.68 ± 4.095.13 ± 4.120.300.32A–10.95 ± 2.839.13 ± 2.947.96 ± 3.187.00 ± 3.913.82 ± 4.169UKUC–0.31 ± 0.710.0390.62A–0 Effect of interventions on clinical assessment scales. Table 4Effect of interventions on haematological and biochemical variables.Table 4Sl.NoParameterIntervention PeriodControl Group (Mean + S.D.)Ayurveda Group (Mean + S.D.)pEffect Size (0–60 days)1Haemoglobin (mg/dL)0 day12.34 ± 1.7812.28 ± 1.740.750.0160 day12.22 ± 1.3812.14 ± 1.750.8752Serum Creatinine (mg/dl)0 day0.922 ± 0.090.96 ± 0.100.0350.1760 day0.95 ± 0.090.96 ± 0.130.8553Total Bilirubin (mg/dL)0 day0.59 ± 0.100.60 ± 0.091.000.0860 day0.62 ± 0.210.60 ± 0.090.644Direct Biluribin (mg/dL)0 day0.12 ± 0.040.19 ± 0.250.130.3560 day0.11 ± 0.030.11 ± 0.030.735AST (IU/mL)0 day20.72 ± 3.6020.60 ± 4.340.940.0960 day20.22 ± 2.1821.56 ± 4.410.206ALT (IU/mL)0 day18.59 ± 2.2619.69 ± 4.330.190.0860 day19.31 ± 4.5320.08 ± 2.890.507Total Protein (mg/dL)0 day6.70 ± 0.396.69 ± 0.280.700.0760 day6.66 ± 0.286.71 ± 0.270.558Albumin (mg/dL)0 day3.50 ± 0.393.53 ± 0.270.960.0560 day3.58 ± 0.283.59 ± 0.260.939Albumin Globulin ratio0 day1.05 ± 0.141.01 ± 0.040.270.0760 day1.07 ± 0.101.05 ± 0.090.4910Alkaline Phosphatase (IU/mL)0 day83.27 ± 26.9875.17 ± 9.620.050.2560 day118.68 ± 31.79102.43 ± 28.470.078p<0.001<0.001 Effect of interventions on haematological and biochemical variables. Primary outcome Effect of interventions on HDRS was comparable (p = 0.69). Both the groups showed significant improvement at different time points. In control group, improvements were at 15th day (p = 0.011), 30th day (p = 0.06), 45th day (p = 0.001) and at 60th day (p < 0.001). In Ayurveda group, improvements were at 15th day (p = 0.01), 30th day (p = 0.01), 45th day (p < 0.001) and at 60th day (p < 0.001). (Table 3) Secondary outcome- Between group comparison showed significant differences in parameters like PSQI (p = 0.02), WHOQOL-Bref (p < 0.001) and UKU (p = 0.04). PSQI and WHOQOL-Bref showed better improvements in Ayurveda group and PSQI in control group. Other parameters like HARS, BPRS, CGI-S, CGI- GI and CGI-EI showed comparable improvements. (Table 3) Within group assessment in HARS, BPRS, PSQI, WHOQOL-Bref, CGI-S, CGI-GI and CGI-EI showed significant improvement at 30th, 45th, 60th day in both groups. Adverse events were assessed through UKU side effect scale assessment showed, 5 patients in control group had mild adverse events. Events were giddiness (autonomic) (n = 2), inner unrest (psychic) (n = 2), and headache(other side effects) (n = 3). Grade was 1. Duration of the side effects was from 4 days to 6 days. Multiple recurrent side effects were observed during the entire course of the intervention. All adverse events were mild and did not interfere the function of the patient and subsided without any additional interventions. Ayurveda group showed no adverse events. UKU side effect scale assessment showed significant difference with groups favouring Ayurveda group (p = 0.04). (Table 3) Assessments of various blood parameters like haemoglobin, serum creatinine, liver function tests like bilirubin total, bilirubin direct, bilirubin indirect, aspartate amino transferase, alanine amino transferase, alkaline phosphatase, total protein, albumin were within the normal limits at baseline and end of the study. Between group comparison of blood parameters showed changes were comparable. Within group assessments showed both interventions did not produce any significant effect on various blood parameters except in Alkaline phosphatase, where both groups produced significant decrease (<0.001). (Table 4) Discussion The current study showed that Ayurveda interventions (Brahmi vati and Aswagandharishta) had beneficial role in the management of MDD. Ayurveda interventions had better outcomes in quality of life (WHOQOL-BREF) and side effects (UKU scales), Escitalopram was in PSQI. Improvements in both the groups were comparable in parameters like HDRS, HARS, BPRS, CGI-S, CGI-GI and CGI–EI. Both the groups showed anti depressive, anxiolytic, sleep promoting, decreased disease severity, produced global improvement and improved efficacy index. Depression severity reduced from severe to mild. Haemoglobin, liver function test, renal function test parameters were within the normative range and interventions did not produce any significant change except in Alkaline phosphatase. However Alkaline phosphatase values before and after interventions were in normative ranges. Escitalopram produced minor adverse events like giddiness, inner unrest and headache in 5 patients. No side effects were observed with Ayurveda drug intervention and difference in side effect profile was significant (0.04). All the patients were treatment naive and were diagnosed and medicated for the first time. Patients had moderate to severe depression, moderate levels of anxiety, moderately ill (BPRS), poor sleep quality (PSQI) and moderate to markedly ill (CGI severity). Quality of life assessed through WHOQOL-BREF showed that Ayurveda interventions were better and consistent. Effect size was extremely large, which indicates high clinical significance favouring Ayurveda intervention. Reduced improvements in quality of life with escitalopram could be due to minor adverse events. PSQI showed better improvement with Escitalopram and had medium effect size suggesting Escitalopram to have a better improvements on sleep. Aswagandharista and Brahmi vati has various ingredients which have shown psychotrophic and neurotrophic activity. Predominant active ingredients of the Ayurveda interventions could be Aswagandha and Brahmi. Aswagandha acts through hypothalamic pituitary adrenal axis, sympathetic adrenal medullary axis, GABAergic pathways, serotonergic pathways, antioxidant and anti-inflammatory pathways [35]. Glycowithanolides [36] isolated from roots of Withania Somnifera showed antidepressant and anxiolytic effect comparable to imipramine and lorazepam respectively in the elevated plus-maze model. Main active compounds in Bacopa monniera (BM) are saponins comprising of bacosides A, bacopasides I and II, and bacopasaponin C [37]. BM has shown antidepressant activity in preclinical studies. Methanolic extract of BM containing active ingredient bacoside A, showed antidepressant activity comparable to imapramine in an animal model study [38]. Methanolic extract of BM has antidepressant effect in forced swimming test (FST), tail suspension test (TST) and measurement of locomotor activity test (MLAT) [39]. BM prevented the decrease in BDNF expression in the hippocampus of the rats but which was seen in control group rats. It also increased the neurogenesis in the rat hippocampus [40]. Studies have shown chronic unpredictable stress (CUS) induced reduction in BDNF, AKT and CREB expression and are reversed by BM [41]. Clinical study on elderly with BM intervention showed significant reduction in depression and anxiety compared to placebo [42]. Clinical study showed that BM reduced depression to normative levels in patients of Alzheimer's disease however donepezil showed no change [43]. A study of add on effect of BM on anhedonia, a common presentation in depression showed improvements in Hamilton depression rating scale, Snaith–Hamilton Pleasure Scale (SHAPS) compared to citalopram alone [44]. Other ingredients have also demonstrated antidepressant activity in the FST and learned helplessness test models. Methanolic extract of Asparagus racemosus Linn [45] demonstrated antidepressant activity. Petroleum ether extract of Tinospora cordifolia [46] showed antidepressant like activity using TST and FST. Tinospora cordifolia (Wild.) Miers reduced the mouse whole brain monoamine oxidase (MAO-A and MAO-B) activities and resulted in the increase of monoamine levels in the brain. Acorus calamus [47] showed antidepressant activity in the open field behavior (OFB), High Plus Maze (HPM) activity and 5-hydroxytryptamine (5-HT) receptor syndrome in rats. Nardostachys jatamansi (D.Don) DC has antidepressant activity in the TST and open field test (OFT), both extract and fractions have serotonin transporter enhancing activity [48]. Chloroform fraction of total ethanolic extract of Convolvulus pluricaulis [49] Choisy has antidepressant activity in FST and TST by interaction with the adrenergic, dopaminergic, and serotonergic systems. Rubia cordifolia and Tinospora cordifolia attenuate oxidative stress mediated cell injury in rat hippocampal slices subjected to oxygen glucose deprivation and exert neuroprotective [50] effect. Brahmi vati has mineral preparations like Swarna makshika (Cu2SFe2S3) [51] and is also called as chalcopyrite or copper pyrite and Rasa sindoora [52] (Red sulphide of mercury prepared by kupipakva method as explained in the ancient text on Rasa shastra). Mode of action of these Ayurveda drugs could be through the multiple active pharmaceutical ingredient of these products. Therapeutic effects could be due to synergistic therapeutic actions of these agents. Different chemicals can cooperate in agonistic way, may enhance and improve oral drug bioavailability, eliminate adverse events and increase pharmacological potency by drug drug interaction [53]. Pharmacological effects on depression could be through GABAergic pathways, serotonergic pathways, antioxidant and anti-inflammatory pathways. However there is minimal clinical evidence to support the role of BM [54], Withania somnifera and other ingredients in depression. Pharmacological activity of Escitalopram is by inhibiting the reuptake of the serotonin, where tryptaminergic neurons bind to the serotonin transporter (SERT) at the specific [55] site. It's utility in depression and anxiety disorders are well established [48]. There is a scarcity of studies reporting side effects with these plant based medications. Many studies have reported absence of side effects. A study [56] reported side effects of Bacopa monniera as nausea, gastrointestinal upset, intestinal hypermotility which could be due to the cholinergic action. Another animal study [57] reported side effects of BM as decrease in appetite, moderate increase in aspartate aminotransferase, albumin, globulin, urea, nitrogen, and sodium however they were in normative ranges. Concerns with Aswagandharista and Brahmi vati is that they are compound herbal formulations. These have concerns related to clinical reproducibility, standardization of end product due to huge variabilities associated with crude raw herbal materials. Their active constituents of raw drugs may vary due to conditions like geographical conditions, climatic conditions, environmental hazards, collection protocols [58]. Other studies with herbs and Ayurveda medications have showed beneficial effect in patients of depression. A Metanalysis study showed that Crocus sativus (Saffron) [59] has a beneficial effect in MDD. A Randomized controlled phase III clinical trial showed, Rhodiola rosea [60] decreased over all depression, insomnia, emotional instability and somatization in patients of mild and moderate depression. Another study [61] on Rhodiola rosea showed it to produce less antidepressant effect compared to sertraline however had better risk to benefit ratio in mild and moderate depression. Aqueous extract of Piper methysticum (Kava) [62] in patients of generalized anxiety showed antidepressant and anxiolytic activity in a randomized controlled double blind cross over trial. A double blind randomized clinical trial showed that add on therapy with Lavandula angustifolia [63] was effective in MDD. Ayurveda management [64] with Snehapana (Ayurveda therapy of oral intake of Ghee) with cow's Ghee, Virechana (therapeutic purgation) with Abhayadi Modaka, Shirodhara (therapeutic procedure of dripping of medicaments over forehead) with Kshirabala taila for 7 days, AYUSHMAN 15 A (With Ashwagandha) or AYUSHMAN 15 B (without Aswagandha) (Ayurveda formulations) 4.5 gms per day for 2 months in MDD (DSM IV TR) showed significant reduction of depression, reduction on sympathetic tone in heart rate variability parameters and reduction in cortisol. However improvements with AYUSHMAN 15 A & 15 B were comparable. Vamana therapy followed by Unmada Gajankusha Rasa 250 mg twice a day for 90 days [65] showed significant effect in MDD (DSM IV). Brahmi ghruta [66] administered 10 gms twice a day for 6 weeks showed significant improvement in MDD compared to placebo. Same study team has shown that Whole system Ayurveda approach (WSAP) [67] in MDD was superior to escitalopram in parameters of depression, anxiety and sleep profile. WSAP was superior in quality of life and side effect profile which are similar to our current study outcomes. Curcumin and combination of curcumin and saffron were effective in decreasing depression and anxiety in MDD [68]. Additional treatment with herbal medicines [69] in severe depressive episodes showed better response and remission compared to patients without herbal medicines. Herbal medicines enhanced antidepressant response and reduced side effects associated with psychotropic medications. Strengths of the study are randomized controlled trial, standard active control. Comprehensive clinical assessment of depression, anxiety, psychotic symptoms, sleep, quality of life, adverse effects and global severity, improvement and efficacy. Un blinded study is the limitation of the study. Biological assessments like cortisol etc would have given more clarity of the drug action. Further studies with double blind design, larger samples, multi centric studies and with biological assessments can be considered. Conclusion Study demonstrated that Ayurveda interventions with Brahmi vati and Aswangandharista had a beneficial role in the management of MDD. It showed antidepressant, anxiolytic, sleep promoting, improved quality of life, decreased global severity of disease, had global improvement and improvement in efficacy index. Had no adverse effects noted. It showed no changes in the normative values of liver and renal parameters. Efficacy was comparable to Escitalopram. Advantages of Ayurveda interventions over Escitalopram was in lesser side effects and better Quality of life. Source of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors contribution AS- Visualization, Data collection, Writing - Reviewing and Editing. SC- Conceptualization, Methodology, Writing - Original draft preparation, Writing -Reviewing and Editing. BRT- Conceptualization, Methodology, Writing - Original draft preparation, Writing -Reviewing and Editing, Statistical analysis. RT- Visualization, Data collection, Writing - Reviewing and Editing. Declaration on use of generative AI in scientific writing Nothing to disclose. CTRI Registration Number CTRI2019/01/017227. Taxonomy (classification by EVISE): Major Depressive disorder (DSM V), Randomized controlled, parallel group, clinical trial.